{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.54","value":"96.6"},{"groupId":"OG001","spread":"17.45","value":"89.1"},{"groupId":"OG002","spread":"15.22","value":"83.5"},{"groupId":"OG003","spread":"16.88","value":"94.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"23"}],"units":"Participants"}],"description":"Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 9+/-3 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better. Mean and standard deviation of FSIQ were calculated and reported.","dispersionType":"Standard Deviation","groups":[{"description":"Medulloblastoma patients who received regimen A (no carboplatin / no isotretinoin)","id":"OG000","title":"Regimen A (Medulloblastoma Patients)"},{"description":"Medulloblastoma patients who received regimen B (carboplatin / no isotretinoin)","id":"OG001","title":"Regimen B (Medulloblastoma Patients)"},{"description":"Medulloblastoma patients who received regimen C (no carboplatin / isotretinoin)","id":"OG002","title":"Regimen C (Medulloblastoma Patients)"},{"description":"Medulloblastoma patients who received regimen D (carboplatin / isotretinoin)","id":"OG003","title":"Regimen D (Medulloblastoma Patients)"}],"paramType":"MEAN","populationDescription":"Eligible medulloblastoma patients are included.","reportingStatus":"POSTED","timeFrame":"6 - 12 months post diagnosis","title":"The Estimated Full-scale IQ (FSIQ) at 9+/-3 Months Post Diagnosis for Medulloblastoma Patients","type":"SECONDARY","unitOfMeasure":"Score on a scale"}